Aldo-DHF: spironolactone improves diastolic function

Heart failure with preserved ejection fraction (HF-PEF) accounts for more than 50% of heart failure cases. To date, medical therapy has failed to show improvements in diastolic dysfunction, cardiac remodelling, or cardiovascular outcomes. As mineralocorticoid receptor activation by aldosterone contributes to the pathophysiology of HF through several different mechanisms, the Aldosterone Receptor Blockade in Diastolic […]

Read More…

Diastolic dysfunction leads to decreased exercise capacity

Determining the most important parameters affecting exercise performance, particularly in relation to age, could have important implications for rehabilitation.¬† Although a reduction in maximal heart rate is known to be important, previous studies have implied that left ventricular systolic function did not correlate with maximal exercise time. […]

Read More…